CXCR4(S338X) clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

CXCR4(S338X) clonality ≥25% is associated with lower very good partial response and shorter progression-free survival to ibrutinib. CXCR4(S338X) clonality assessment represents a novel biomarker to predict outcomes to ibrutinib in Waldenström macroglobulinemia patients.

Na minha lista:
書目詳細資料
發表在:Blood Adv
Main Authors: Gustine, Joshua N., Xu, Lian, Tsakmaklis, Nicholas, Demos, Maria G., Kofides, Amanda, Chen, Jiaji G., Liu, Xia, Munshi, Manit, Guerrera, Maria Luisa, Chan, Gloria G., Patterson, Christopher J., Keezer, Andrew, Meid, Kirsten, Dubeau, Toni, Yang, Guang, Hunter, Zachary R., Treon, Steven P., Castillo, Jorge J.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2019
主題:
Stimulus Report
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784519/
https://ncbi.nlm.nih.gov/pubmed/31570491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000635
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍